{"id":59259,"date":"2026-03-11T14:06:32","date_gmt":"2026-03-11T06:06:32","guid":{"rendered":"https:\/\/flcube.com\/?p=59259"},"modified":"2026-03-11T14:06:33","modified_gmt":"2026-03-11T06:06:33","slug":"pfizers-tilrekimig-hits-phase-2-primary-endpoint-il-4-il-13-tslp-trispecific-shows-52-easi-75-response-in-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59259","title":{"rendered":"Pfizer&#8217;s Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\/IL-13\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) announced <strong>positive topline results<\/strong> from a <strong>Phase 2 study<\/strong> of <strong>tilrekimig (PF-07275315)<\/strong>, an <strong>investigational trispecific antibody<\/strong> targeting <strong>IL-4, IL-13, and TSLP<\/strong>, in <strong>adults with moderate-to-severe atopic dermatitis (AD)<\/strong>. The study <strong>met its primary endpoint<\/strong>, with <strong>tilrekimig demonstrating statistically significant EASI-75 responses<\/strong> versus placebo, including <strong>51.9% placebo-adjusted response at the middle dose<\/strong> with <strong>monthly dosing<\/strong>. The favorable efficacy and safety profile supports <strong>acceleration to Phase 3<\/strong>, with a <strong>pivotal AD study planned for 2026 initiation<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results\">Clinical Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Tilrekimig (Low\/Mid\/High Dose)<\/th><th>Placebo<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary: EASI-75 at Week 16<\/strong><\/td><td>38.7% \/ <strong>51.9%<\/strong> \/ 49.4% (placebo-adjusted)<\/td><td>Reference<\/td><td><strong>Statistically significant; dose-responsive efficacy<\/strong><\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>Monthly (Stage 2 evaluation)<\/td><td>\u2014<\/td><td>Competitive with Q2W\/Q4W standard biologics<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Well-tolerated; favorable profile<\/td><td>\u2014<\/td><td>No unexpected safety signals<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Stage 1: dose-ranging; Stage 2: monthly dosing confirmation<\/td><td>\u2014<\/td><td>Robust Phase 2b design<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>EASI-75 Context:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eczema Area and Severity Index 75% improvement<\/strong> \u2013 standard AD efficacy endpoint<\/li>\n\n\n\n<li><strong>51.9% mid-dose response<\/strong> competitive with dupilumab (~50-60%) and lebrikizumab (~50%) in similar populations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Tilrekimib (PF-07275315) Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Trispecific antibody (first-in-class mechanism)<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td><strong>IL-4 + IL-13 + TSLP<\/strong> (three key Th2 cytokines)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Simultaneous blockade of: \u2022 IL-4\/IL-13 (Th2 inflammation, barrier dysfunction)<br>\u2022 TSLP (upstream master switch for Type 2 immunity)<\/td><\/tr><tr><td><strong>Synergy<\/strong><\/td><td>Comprehensive Th2 pathway shutdown vs. single or dual targeting<\/td><\/tr><tr><td><strong>Dosing Potential<\/strong><\/td><td>Once-monthly (supported by Stage 2 data)<\/td><\/tr><tr><td><strong>Indications in Development<\/strong><\/td><td>Atopic dermatitis (lead); asthma; chronic obstructive pulmonary disease (COPD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Scientific Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL-4\/IL-13:<\/strong> Established AD drivers (dupilumab target); barrier repair and pruritus control<\/li>\n\n\n\n<li><strong>TSLP:<\/strong> Upstream amplifier; tezepelumab validated target for severe, refractory disease<\/li>\n\n\n\n<li><strong>Trispecific Advantage:<\/strong> Single molecule achieves triple blockade; potential for superior efficacy in heterogeneous AD populations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-development-outlook\">Strategic Context &amp; Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase 3 Acceleration<\/strong><\/td><td>Pivotal AD study on track for 2026 start; rapid progression given competitive urgency<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Challenges dupilumab (IL-4R\u03b1) and lebrikizumab (IL-13) with triple mechanism; monthly dosing convenience advantage<\/td><\/tr><tr><td><strong>Respiratory Expansion<\/strong><\/td><td>Asthma and COPD indications leverage same Th2 biology; platform potential across inflammatory franchise<\/td><\/tr><tr><td><strong>Pfizer Immunology<\/strong><\/td><td>Complements abrocitinib (JAK1, oral) with biologic option; addresses unmet need in moderate-severe AD<\/td><\/tr><tr><td><strong>Revenue Potential<\/strong><\/td><td>AD market alone $15+ billion globally; tilrekimig could capture 10-15% share if approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Dosing<\/th><th>Tilrekimig Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Sanofi\/Regeneron<\/strong><\/td><td>Dupixent (dupilumab)<\/td><td>IL-4R\u03b1 blockade (IL-4 + IL-13)<\/td><td>Q2W<\/td><td>Adds TSLP targeting; monthly convenience<\/td><\/tr><tr><td><strong>Eli Lilly<\/strong><\/td><td>Ebglyss (lebrikizumab)<\/td><td>IL-13 mAb<\/td><td>Q2W\/Q4W<\/td><td>Triple vs. single cytokine blockade<\/td><\/tr><tr><td><strong>Amgen\/AZ<\/strong><\/td><td>Tezspire (tezepelumab)<\/td><td>TSLP mAb<\/td><td>Q4W<\/td><td>Adds IL-4\/IL-13 for comprehensive Th2 suppression<\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td><strong>Tilrekimig<\/strong><\/td><td><strong>IL-4 + IL-13 + TSLP trispecific<\/strong><\/td><td><strong>Monthly<\/strong><\/td><td><strong>First trispecific; potential best-in-class efficacy<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline\">Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase 2<\/strong><\/td><td>Complete<\/td><td>Efficacy, dose-ranging, monthly dosing confirmation<\/td><\/tr><tr><td><strong>Phase 3 (AD)<\/strong><\/td><td>2026 initiation<\/td><td>Pivotal efficacy vs. placebo and\/or active comparator; safety database expansion<\/td><\/tr><tr><td><strong>Phase 2\/3 (Asthma)<\/strong><\/td><td>2026-2027<\/td><td>Proof-of-concept in Th2-high asthma; exacerbation reduction<\/td><\/tr><tr><td><strong>Phase 2 (COPD)<\/strong><\/td><td>2027+<\/td><td>Th2-endotype COPD evaluation<\/td><\/tr><tr><td><strong>NDA Filing<\/strong><\/td><td>2028-2029<\/td><td>U.S., EU, Japan simultaneous submissions anticipated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase 3 initiation timelines, competitive positioning, and market potential for tilrekimig. Actual results may differ due to trial execution risks, competitive dynamics with established biologics, and manufacturing scale-up for trispecific antibody production.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,28,863,309],"class_list":["post-59259","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-multi-specific-antibodies","tag-nyse-pfe","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer&#039;s Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\/IL-13\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody targeting IL-4, IL-13, and TSLP, in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, with tilrekimig demonstrating statistically significant EASI-75 responses versus placebo, including 51.9% placebo-adjusted response at the middle dose with monthly dosing. The favorable efficacy and safety profile supports acceleration to Phase 3, with a pivotal AD study planned for 2026 initiation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59259\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer&#039;s Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\/IL-13\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody targeting IL-4, IL-13, and TSLP, in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, with tilrekimig demonstrating statistically significant EASI-75 responses versus placebo, including 51.9% placebo-adjusted response at the middle dose with monthly dosing. The favorable efficacy and safety profile supports acceleration to Phase 3, with a pivotal AD study planned for 2026 initiation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59259\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T06:06:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T06:06:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59259#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59259\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer&#8217;s Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\\\/IL-13\\\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis\",\"datePublished\":\"2026-03-11T06:06:32+00:00\",\"dateModified\":\"2026-03-11T06:06:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59259\"},\"wordCount\":519,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Multi-specific antibodies\",\"NYSE: PFE\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59259#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59259\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59259\",\"name\":\"Pfizer's Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\\\/IL-13\\\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-11T06:06:32+00:00\",\"dateModified\":\"2026-03-11T06:06:33+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody targeting IL-4, IL-13, and TSLP, in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, with tilrekimig demonstrating statistically significant EASI-75 responses versus placebo, including 51.9% placebo-adjusted response at the middle dose with monthly dosing. The favorable efficacy and safety profile supports acceleration to Phase 3, with a pivotal AD study planned for 2026 initiation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59259#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59259\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59259#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer&#8217;s Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\\\/IL-13\\\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer's Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\/IL-13\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody targeting IL-4, IL-13, and TSLP, in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, with tilrekimig demonstrating statistically significant EASI-75 responses versus placebo, including 51.9% placebo-adjusted response at the middle dose with monthly dosing. The favorable efficacy and safety profile supports acceleration to Phase 3, with a pivotal AD study planned for 2026 initiation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59259","og_locale":"en_US","og_type":"article","og_title":"Pfizer's Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\/IL-13\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis","og_description":"Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody targeting IL-4, IL-13, and TSLP, in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, with tilrekimig demonstrating statistically significant EASI-75 responses versus placebo, including 51.9% placebo-adjusted response at the middle dose with monthly dosing. The favorable efficacy and safety profile supports acceleration to Phase 3, with a pivotal AD study planned for 2026 initiation.","og_url":"https:\/\/flcube.com\/?p=59259","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T06:06:32+00:00","article_modified_time":"2026-03-11T06:06:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59259#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59259"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer&#8217;s Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\/IL-13\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis","datePublished":"2026-03-11T06:06:32+00:00","dateModified":"2026-03-11T06:06:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59259"},"wordCount":519,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Multi-specific antibodies","NYSE: PFE","Pfizer"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59259#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59259","url":"https:\/\/flcube.com\/?p=59259","name":"Pfizer's Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\/IL-13\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-11T06:06:32+00:00","dateModified":"2026-03-11T06:06:33+00:00","description":"Pfizer Inc. (NYSE: PFE) announced positive topline results from a Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody targeting IL-4, IL-13, and TSLP, in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, with tilrekimig demonstrating statistically significant EASI-75 responses versus placebo, including 51.9% placebo-adjusted response at the middle dose with monthly dosing. The favorable efficacy and safety profile supports acceleration to Phase 3, with a pivotal AD study planned for 2026 initiation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59259#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59259"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59259#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer&#8217;s Tilrekimig Hits Phase 2 Primary Endpoint \u2013 IL-4\/IL-13\/TSLP Trispecific Shows 52% EASI-75 Response in Atopic Dermatitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59259"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59259\/revisions"}],"predecessor-version":[{"id":59261,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59259\/revisions\/59261"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}